Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Rosen

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
British Journal of Psychology (London, England : 1953)|September 16, 2014
Examining the relationships between self-efficacy, task-relevant attentional control , and task performance: Evidence from event-related brain potentialsJason R Themanson, Peter J Rosen
Psychophysiology|July 9, 2014
The effects of social exclusion on the ERN and the cognitive control of action monitoringJason R Themanson, Aaron B Ball, Stephanie M Khatcherian, et al.
Social Cognitive and Affective Neuroscience|May 12, 2012
An event-related examination of neural activity during social interactionsJason R Themanson, Stephanie M Khatcherian, Aaron B Ball, et al.
Brain and Cognition|September 4, 2012
Alterations in error-related brain activity and post-error behavior over timeJason R Themanson, Peter J Rosen, Matthew B Pontifex, et al.
Annals of Hematology|August 20, 2013
Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphomaJeffrey L Vacirca, Peter I Acs, Imad A Tabbara, et al.
AJR. American Journal of Roentgenology|November 26, 2009
Triple-drug transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: assessment of survival in 124 consecutive patientsAntoinette S Gomes, Michael H Rosove, Peter J Rosen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2012
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphomaMelissa Alsina, Suzanne Trudel, Richard R Furman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2010
A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumorsPeter J Rosen, Christopher J Sweeney, Dorothy J Park, et al.
Cancer Chemotherapy and Pharmacology|August 27, 2013
A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumorsKyriakos P Papadopoulos, Howard A Burris, Michael Gordon, et al.
British Journal of Haematology|November 23, 2017
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myelomaAlexa Cohen, Tanya M Spektor, Laura Stampleman, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
British Journal of Psychology (London, England : 1953)|September 16, 2014
Examining the relationships between self-efficacy, task-relevant attentional control , and task performance: Evidence from event-related brain potentialsJason R Themanson, Peter J Rosen
Psychophysiology|July 9, 2014
The effects of social exclusion on the ERN and the cognitive control of action monitoringJason R Themanson, Aaron B Ball, Stephanie M Khatcherian, et al.
Social Cognitive and Affective Neuroscience|May 12, 2012
An event-related examination of neural activity during social interactionsJason R Themanson, Stephanie M Khatcherian, Aaron B Ball, et al.
Brain and Cognition|September 4, 2012
Alterations in error-related brain activity and post-error behavior over timeJason R Themanson, Peter J Rosen, Matthew B Pontifex, et al.
Annals of Hematology|August 20, 2013
Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphomaJeffrey L Vacirca, Peter I Acs, Imad A Tabbara, et al.
AJR. American Journal of Roentgenology|November 26, 2009
Triple-drug transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: assessment of survival in 124 consecutive patientsAntoinette S Gomes, Michael H Rosove, Peter J Rosen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2012
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphomaMelissa Alsina, Suzanne Trudel, Richard R Furman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2010
A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumorsPeter J Rosen, Christopher J Sweeney, Dorothy J Park, et al.
Cancer Chemotherapy and Pharmacology|August 27, 2013
A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumorsKyriakos P Papadopoulos, Howard A Burris, Michael Gordon, et al.
British Journal of Haematology|November 23, 2017
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myelomaAlexa Cohen, Tanya M Spektor, Laura Stampleman, et al.
Pageof 2